R. Sanborn

发表

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.

C. Rudin, E. Schmidt, H. Pandha, 2017 .

Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

J. Neal, H. Wakelee, C. Liang, 2016 .

OX40 is a potent immune-stimulating target in late-stage cancer patients.

B. Fox, N. Morris, T. Crocenzi, 2013, Cancer research.

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa L. Johnson, A. El-Khoueiry, J. Rodon, 2021, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

K. Steele, N. Rizvi, A. Balmanoukian, 2015 .

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.

M. Socinski, S. Novello, F. Barlesi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumors and the evolution of targeted therapy.

C. Blanke, R. Sanborn, 2005, Clinical advances in hematology & oncology : H&O.

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.

F. Hirsch, D. Gandara, W. Franklin, 2013, Clinical lung cancer.

Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.

R. Sanborn, D. Sauer, 2008, Dermatologic clinics.

Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer

K. Steele, J. Chaft, A. Gupta, 2018 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

AN IMMUNOTHERAPY TRIO IN ADVANCED FOR COORDINATED

F. Lund-Johansen, B. Fox, B. Piening, 2020 .

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

D. Gerber, I. Bondarenko, W. Su, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

H. Wakelee, J. Nieva, T. Shaffer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer.

S. Senan, S. Gadgeel, R. Sanborn, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

A. Jimeno, B. Sikic, M. Sznol, 2022, Journal for ImmunoTherapy of Cancer.

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

D. Camidge, L. Chow, T. Yap, 2021, The oncologist.

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

P. Ascierto, E. Lipson, F. Hodi, 2017 .

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

R. Govindan, A. Mansfield, Y. Lou, 2021, Clinical Cancer Research.

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer A C

R. Govindan, Y. Lou, N. Gabrail, 2021 .

A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

R. Govindan, A. Mansfield, Y. Lou, 2021 .

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2014 .

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

W. Stock, A. Wickrema, D. Peace, 2001, Bone Marrow Transplantation.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

K. Steele, N. Rizvi, J. Chaft, 2016, The Lancet. Oncology.

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

M. Dhodapkar, M. Sznol, H. Kluger, 2014, Science Translational Medicine.

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

M. Gleave, J. Nemunaitis, G. Nicholas, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

L. Trani, Y. Ohe, E. Felip, 2022, Journal of Clinical Oncology.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

B. Fox, W. Urba, E. Walker, 2017, Journal of Immunotherapy for Cancer.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Erlotinib: applications in therapy and current status of research

A. Davies, R. Sanborn, 2009, Expert review of clinical pharmacology.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The safety of bevacizumab

A. Sandler, R. Sanborn, 2006, Expert opinion on drug safety.

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.

J. Crowley, J. Villano, K. Chansky, 2020, Clinical lung cancer.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)

J. Villano, K. Chansky, G. Weiss, 2017, Investigational New Drugs.

555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

A. Patnaik, S. Piha-Paul, A. Dowlati, 2021, Annals of Oncology.

A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

N. Hanna, J. Patel, G. Masters, 2017, Cancer.

Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

R. Sanborn, C. Blanke, 2005, Seminars in oncology.

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

P. Moore, J. Bendell, J. Luke, 2020, Cell reports. Medicine.

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

S. Novello, V. Papadimitrakopoulou, P. Dubray-Longeras, 2018, Journal of Thoracic Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

D. Schadendorf, P. Ascierto, R. Dummer, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Donnell, T. Curiel, M. Rebelatto, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?

R. Sanborn, 2008, Current treatment options in oncology.

Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement.

B. Lally, R. Sanborn, 2008, Thoracic surgery clinics.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.

T. Curiel, M. Rebelatto, N. Segal, 2016 .

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

A Placebo‐Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First‐Line Treatment of Patients With Advanced Nonsquamous Non–Small‐Cell Lung Cancer and Systemic Inflammation

G. Giaccone, G. Kennealey, A. Martínez-Martí, 2018, Clinical Lung Cancer.

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients.

C. Rudin, H. Pandha, D. Gerber, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

H. Wakelee, R. Osarogiagbon, J. Latz, 2012, Lung cancer.

P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

N. Hanna, G. Otterson, R. Hall, 2021 .

Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting

M. Dhodapkar, M. Sznol, H. Kluger, 2014 .

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

L. Sequist, M. Edelman, M. Tan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).

J. Nemunaitis, J. Marshall, R. Finn, 2017 .

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

F. Meric-Bernstam, P. LoRusso, J. Harding, 2020 .

Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis

D. Camidge, L. Chow, H. Burris, 2018, Clinical research.

Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease.

Charles R. Thomas, Shilpen A. Patel, R. Sanborn, 2008, Thoracic surgery clinics.

Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.

Charles R. Thomas, B. Tieu, R. Sanborn, 2008, Thoracic surgery clinics.

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

O. Vasiljeva, G. V. van Dongen, F. Meric-Bernstam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers

R. Epstein, R. Sanborn, T. Salimi, 2021, Journal of medical economics.

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

R. Plummer, E. D. de Vries, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

L. Trani, Y. Ohe, E. Felip, 2021, Annals of Oncology.

375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

M. Socinski, S. Novello, P. Dubray-Longeras, 2020 .

Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

N. Rizvi, H. Kluger, M. Callahan, 2016 .

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer

N. Mattek, A. Benson, H. Lenz, 2018, American journal of clinical oncology.

Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.

N. Rizvi, H. Kluger, M. Callahan, 2017 .

Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.

R. Govindan, A. Mansfield, Y. Lou, 2020, Journal of Clinical Oncology.

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

O. Hamid, J. Gray, L. Chow, 2016 .

MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients

J. Neal, H. Wakelee, J. Nieva, 2017 .

Results of Lung Cancer Screening in the Community

Mansen Wang, R. Sanborn, S. Zinck, 2020, The Annals of Family Medicine.

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results.

E. Cho, K. Bae, E. Attiyeh, 2018, Annals of Oncology.

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

K. Steele, M. Rebelatto, N. Rizvi, 2015, Journal of Immunotherapy for Cancer.

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

L. Vitale, N. Bhardwaj, M. O'Hara, 2019, Immunology.

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

H. Lenz, G. Schwartz, A. Bullock, 2023, Journal of Clinical Oncology.

Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies

B. Fox, W. Urba, B. Curti, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

A. El-Khoueiry, H. Mamdani, A. Spira, 2020 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

C. Dubay, B. Fox, B. Spieler, 2014, Journal of Immunotherapy for Cancer.

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC

C. Dubay, B. Fox, B. Spieler, 2015, Journal of Immunotherapy for Cancer.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

B. Fox, N. Morris, T. Crocenzi, 2013, Cancer research.

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

M. Gleave, J. Nemunaitis, G. Nicholas, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

H. Wakelee, T. Owonikoko, S. Ramalingam, 2021 .

SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

D. Davar, G. Curigliano, S. Ansell, 2021 .

731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)

A. Patnaik, Juanita Lopez, S. Piha-Paul, 2022, Regular and Young Investigator Award Abstracts.